Eyes that photosynthesise: NUS scientists plant a cure for dry eye disease

AI News Q&A (Free Content)

Q1: What is the new photosynthetic treatment developed by NUS scientists for dry eye disease?

A1: Researchers at the National University of Singapore have developed an innovative treatment for dry eye disease using a photosynthetic method. They extracted thylakoid grana from spinach plants and transplanted them into corneal cells. This method allows the eyes to utilize light to produce NADPH, which helps in maintaining continuous hydration and healing of the eyes. This treatment, delivered via eye drops, has shown promising results in preclinical studies, outperforming existing treatments like Restasis®.

Q2: How does the photosynthetic mechanism work in the treatment of dry eye disease?

A2: The treatment involves using a light-activated technology derived from spinach plant thylakoids, which are responsible for photosynthesis. When these thylakoids are transplanted into the eye's corneal cells, they function as a dedicated NADPH factory, producing this molecule upon exposure to ambient light. NADPH plays a crucial role in cellular repair and hydration, aiding in the healing process of the eyes affected by dry eye disease.

Q3: What are the potential advantages of using plant-based photosynthetic treatments over traditional methods for eye diseases?

A3: Plant-based photosynthetic treatments offer several advantages, including being non-invasive and utilizing a natural process to heal the eyes. Unlike synthetic drugs, this method harnesses ambient light to activate biological processes similar to photosynthesis, potentially reducing side effects. The NUS study showed that this approach not only effectively reversed corneal damage but also worked quickly, within five days, to restore eye health.

Q4: What is the significance of using thylakoid grana in the new NUS treatment for dry eyes?

A4: Thylakoid grana are crucial components in the photosynthesis process, containing the light-dependent reactions that produce NADPH. In the NUS treatment, these thylakoid grana enable corneal cells to perform photosynthesis-like reactions, producing NADPH upon light exposure. This molecule is essential for healing as it combats oxidative stress and aids in cellular repair, providing a novel way to treat dry eyes by mimicking plant processes.

Q5: How does the new eye treatment developed by NUS scientists compare to existing treatments for dry eye disease?

A5: In comparison to existing treatments like Restasis®, the NUS-developed eye drops have demonstrated superior efficacy in preclinical trials. The plant-based treatment not only speeds up the healing process, effectively reversing corneal damage to near-healthy levels within a few days, but it also does so without interfering with color perception. This makes it a safer and more effective alternative for patients suffering from dry eye disease.

Q6: What are the potential broader implications of this photosynthetic technology in medical treatments?

A6: The broader implications of this technology could extend to other medical treatments that require cellular repair and regeneration. By leveraging photosynthesis-like processes, this approach could potentially be applied to other inflammatory or degenerative conditions, offering a natural and effective alternative to synthetic drugs. This method could revolutionize treatments by reducing side effects and utilizing the body's own processes for healing.

Q7: What recent scholarly research supports the feasibility of using photosynthetic nanothylakoids in medical treatments?

A7: A recent study published in 2025 demonstrated the use of photosynthetic nanothylakoids in treating rheumatoid arthritis by reprogramming inflammatory macrophages. This research highlights the potential of photosynthetic processes in medical treatments, as it showed significant improvement in reducing inflammation and promoting regeneration in animal models. This supports the feasibility of applying similar principles in treating eye diseases like dry eye.

References:

• Bioengineered photosynthetic nanothylakoids reshape the inflammatory microenvironment for rheumatoid arthritis therapy.